Other News To Note
• Lpath Inc., of San Diego, said it used its discovery technology to generate several monoclonal antibody product candidates targeting the leukotriene family of bioactive lipids. Leukotrienes are implicated in numerous inflammatory processes, and the company said the lead antibody, which is designed to bind to and neutralize several different leukotriene isoforms, has shown positive in vivo results and testing is under way in animal models of respiratory diseases, including asthma.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter